Qual é o preço para Graybug Vision, Inc. (GRAY)

O preço para Graybug Vision, Inc. (GRAY) é $2.70

Qual é a capitalização de mercado para Graybug Vision, Inc. (GRAY)

A capitalização de mercado para Graybug Vision, Inc. (GRAY) é $4.13M

Histórico de Preços de Graybug Vision, Inc. (GRAY)

Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.

Ano	Desempenho
2023	-59.99%
2022	-72.75%
2021	-92.01%
2020	0.00%

Ano

Desempenho

2023

-59.99%

2022

-72.75%

2021

-92.01%

2020

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$505.24	28.63%	US
Argenx SE ARGX.US	$846.09	29.41%	NL
Lonza Group AG LONN.SW	$731.69	6.47%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$251.82	11.75%	BE

Empresa

Preço da ação

Variação 1a%

País